ARTICLE | Clinical News
DCVax-Brain: NWBT will begin this quarter a U.S. Phase II trial of DCVax-Brain in 90 patients with glioblastoma.
February 11, 2002 8:00 AM UTC
Northwest Biotherapeutics Inc. (NWBT), Bothell, Wash. Product: DCVax-Brain Business: Cancer Therapeutic category: Immune stimulation Target: Cancer cells Description: Dendritic cells loaded with glio...